FDA authorizes Pfizer-BioNTech COVID-19 vaccine boosters for certain populations

Editor's Note

The Food and Drug Administration (FDA) on September 22 amended the emergency use authorization (EUA) for Pfizer-BioNTech’s COVID-19 vaccine to allow for use of a single booster to be administered at least 6 months after completion of the primary series in those:

• 65 years of age and older
• 18 through 64 years of age at high risk of severe COVID-19
• 18 through 64 years of age whose frequent institutional or occupational exposure to COVID-19 puts them at high risk of serious complications of COVID-19, including severe COVID-19.

The authorization applies only to the Pfizer-BioNTech vaccine.